The overexpression of ACO and CPT-1 may involve the hepatoprotective effects of GP and Gypenoside XL on NAFLD by regulating mitochondrial fatty acid β-oxidation. Here, KLK15 is linked to metabolic dysfunction-associated steatotic liver disease.